[Federal Register Volume 61, Number 76 (Thursday, April 18, 1996)]
[Notices]
[Pages 16926-16927]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-9527]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health.
ACTION: Notice.
-----------------------------------------------------------------------
The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for U.S. companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804 (telephone 301/496-7057; fax 301/402-0220). A
signed Confidential Disclosure Agreement (CDA) will be required to
receive copies of the patent applications.
Dimeric Arylisoquinoline Alkaloids and Synthesis Methods Thereof
Bringmann, G., Boyd, M.R., Gotz, R., Kelly, T.R. (NCI)
Filed 23 Dec 94
Serial No. 08/363,684
Licensing Contact: Gloria Richmond, 301/496-7056 ext 268
The present invention relates to a new method of chemical synthesis
of known and new dimeric arylisoquinoline alkaloids. These compounds
are members of a general class known as naphthylisoquinoline alkaloids.
These dimeric alkaloids have been found to be effective inhibitors of
HIV replication in human immune cells. The method of this invention
provides access not only to known but also heretofore unknown medically
useful compounds. The invention also provides for new dimeric
arylisoquinoline compounds and derivatives thereof. (portfolio:
Infectious Diseases--Therapeutics, antivirals, AIDS)
Dimeric Naphthylisoquinoline Alkaloids and Synthesis Methods Thereof
Bringmann, G., Harmsen, S., Boyd, M.R. (NCI)
Filed 22 July 94
Serial No. 08/279,339
Licensing Contact: Gloria Richmond, 301/496-7056 ext 268
This invention embodies the synthesis of homodimeric and
heterodimeric naphthylisoquinoline alkaloids and derivatives. The
methods presented in the invention are advantageous because they
permit, for the first time, the in vitro synthesis of compounds for
which the only known natural source is the rare tropical vine,
Ancistrocladus korupensis of Central Africa. This class of compounds
has been demonstrated to be effective in inhibiting the ability of HIV
to replicate and infect cells. Therefore, the dimeric alkaloids appear
to comprise a novel class of antiviral drugs that may be very useful by
themselves or in combination with other treatments. (portfolio:
Infectious Diseases--Therapeutics, antivirals, AIDS)
[[Page 16927]]
Monomeric Naphthylisoquinoline Alkaloids and Synthesis Methods Thereof
Bringmann, G., Gotz, R., Boyd, M.R. (NCI)
Filed 22 Jul 94
Serial No. 08/279,291
Licensing Contact: Gloria Richmond, 301/496-7056 ext 268
Monomeric naphthylisoquinoline alkaloids and their derivatives are
medically useful for the treatment of parasitic infections including
malaria. However, these particular alkaloids are available in a limited
supply since they are obtained from scarce plants which have a limited
geographic distribution. This invention embodies methods for the
preparation of monomeric naphthylisoquinoline alkaloids, including the
antiparasitic korupensamines and related compounds, as well as non-
korupensamines. New, medically useful, naphthylisoquinoline compounds
and derivatives are also described. (portfolio: Infectious Diseases--
Therapeutics, anti-parasitic)
Antimalarial Naphthylisoquinoline Alkaloids and Pharmaceutical
Compositions and Medicinal Uses Thereof
Francois, G., Bringmann, G., Phillipson, J.D., Boyd, M.R., Assi, L.A.,
Dochez, G., Schneider, C., Timperman, G. (NCI)
Filed 14 Feb 94
Serial No. 08/195,547
Licensing Contact: Gloria Richmond, 301/496-7056 ext 268
This is a new class of napthylisoquinoline alkaloid compounds,
present in plant species of the Ancistrocladaceae and Dioncophyllaceae
plant families which are found in tropical Africa and southern and
southeast Asia, that exhibit effective antimalarial properties and
offer important new weapons in the treatment of this devastating
disease. The deadliest malarial parasites have become resistant to
previously effective antimalarial drugs; therefore, effective new
antimalarial drugs are urgently needed. These new naphthylisoquinoline
compounds effectively inhibit the growth, reproduction, and pathologic
effects of a broad spectrum of Plasmodia parasites, including drug-
resistant strains. Licensees of this invention will be required to
comport with all applicable federal and country-of-collection policies
relating to biodiversity. (portfolio: Infectious Diseases--
Therapeutics, anti-parasitic)
Antimalarial Korupensamines and Pharmaceutical Compositions and Medical
Uses Thereof
Boyd, M.R., Francois, G., Bringmann, G., Hallock, Y.F., Manfredi, K.P.,
Cardellina, J.H. (NCI)
Serial No. 08/195,260
U.S. Patent No. 5,409,938 issued 25 Apr 95
Licensing Contact: Steve Ferguson, 301/496-7735 ext 266
The class of compounds known as korupensamines exhibit in vitro and
in vivo antimalarial activity and offer a potent new means for treating
and controlling this devastating disease. As many as 2-3 million people
worldwide die from malaria each year, and many more suffer from long-
term chronic infection. The deadliest malarial parasites have become
resistant to previously effective antimalarial drugs such as
chloroquine and other clinically useful agents; therefore, effective
new antimalarial drugs are urgently needed. These korupensamine
compounds, which are isolated from a new species of the plant genus
Ancistrocladus which is found in tropical Africa and southern and
southeast Asia, effectively inhibit the growth, reproduction, and
pathologic effects of a broad spectrum of Plasmodia parasites when
given alone or in conjunction with previously available antimalarial
agents. Licensees of this invention will be required to comport with
all applicable federal and country-of-collection policies relating to
biodiversity. (portfolio: Infectious Diseases--Therapeutics, anti-
parasitic)
Michellamine Antiviral Agents, Compositions, and Treatment Methods
Boyd, M.R., Cardellina, J.H., Manfredi, K.P., Blunt, J.W., Pannell,
L.K., McMahon, J.B., Gulakowski, R.J., Cragg, G.M., Bringmann, G.,
Thomas, D., Jato, J. (NCI)
U.S. Patent 5,455,251 issued 3 Oct 95
Serial No. 08/049,824 (CIP of 07/684,197 with a priority date of 12 Apr
91)
Licensing Contact: Gloria H. Richmond, 301/496-7056 ext 268
Michellamines, structurally novel naphthalene
tetrahydroisoquinoline alkaloids, are a new class of antiviral
compounds present in the plant Ancistrocladus korupensis. The
Ancitrocladaceae is a small paleotropical family, with 20 species known
from Asia and tropical Africa. A. korupensis contains three distinct
michellamines, A, B, and C. Michellamine B, the most prevalent and
potent of the three, is capable of inhibiting two distinct stages of
the HIV life cycle. The compound is able to inhibit HIV-induced cell
killing of infected cells but has no effect on HIV virons or initial
binding of HIV to target cells. In addition, michellamine B inhibits
the enzymatic activity of both the normal HIV reverse transcriptase and
the activity of several mutant transcriptases which are resistant to
several nonucleoside inhibitors. The claims of this invention relate to
michellamine compounds and derivatives, methods for the isolation of
the michellamines from A. korupensis, and methods for the
administration of these antiviral compounds for treating patients
infected with HIV. Licensees of this invention will be required to
comport with all applicable federal and country-of-collection policies
relating to biodiversity. (portfolio: Infectious Diseases--
Therapeutics, anti-virals, AIDS)
Dated: April 9, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-9527 Filed 4-17-96; 8:45 am]
BILLING CODE 4140-01-M
